Private equity wants in on your 401(k). What you need to know before investing
Chances are very good that your 401(k) does not currently offer you access to private equity investments, which, as the name implies, are investments in companies that are not publicly traded.
The question is, will that change in the next few years? And, if it does, is it worth it for you to invest?
Large company pension plans and university endowments — both of which have very long time horizons — have invested for years in private equity and private debt funds. But 401(k)s typically haven't offered those options to plan participants. In November 2024, only 2.4% of 401(k) sponsors said they added a private equity investment option to their plan, according to a weekly poll question from the Plan Sponsor Council of America.
That may be because employers are afraid of potential lawsuits if they include those options, which typically charge investors more than investment funds in public companies. And under the Employment Retirement Security Act (ERISA), employers have a fiduciary duty to ensure that investment options in your 401(k) are prudent and have reasonable fees, said Jerry Schlichter, founding partner of Schlichter Bogard, who pioneered lawsuits against plan sponsors for charging excess 401(k) fees.
It also may be because private assets are riskier to invest in and information about them is opaque, since they're private. So there is less of a requirement to be transparent with investors about how a fund is doing on a regular basis.
In addition, private capital options are considered illiquid investments because you can't take your money out whenever you want. And that may prove too constraining for retirement plan participants, who may need access to their 401(k) money for any number of reasons — including changing or losing a job, Schlichter said.
There has been an increasing push to provide more private capital investment opportunities for retail investors and participants in workplace retirement plans like 401(k)s and 403(b)s.
On the regulatory front, according to Jaret Seiberg, a financial services policy analyst at TD Cowen Washington Research Group, the Trump administration is likely to make it easier to access so-called alternative investments, which include private equity, private real estate and hedge funds.
That could result in an executive order from the president requiring government agencies to expand access to such investments as well as rulemaking or guidance from the Department of Labor — which enforces ERISA — 'to expand the ability of individuals to invest in 401(k) and IRA accounts in alternative investments,' Seiberg said in a daily research note.
There are far fewer public companies today than there were 30 years ago, as more companies remain private.
For that reason, some say, if investors want to own the whole market and have a truly diversified portfolio, where some asset classes move up when others move down, they should have access both to public and private companies.
In a recent conversation with Morningstar, BlackRock chief operating officer Robert Goldstein noted that the performances of publicly traded stocks and bonds have become more correlated than they used to be, and 'many of the less correlated assets are only accessible through the private markets.'
That may be. Or not. For average retail investors, it could be hard to tell because there currently isn't a centralized way to track the performance and underlying investments of private capital funds and directly compare them to that of the stock and bond funds and indexes they're used to.
That's just one reason why other market watchers and investor advocates worry about expanding access to private capital for average retirement savers.
Among those squarely in the camp of those who say employee and retiree nest eggs won't be helped — and could be harmed — by having exposure to private capital is Benjamin Schiffrin, director of securities policy at Better Markets, a nonprofit seeking to promote the public interest in financial markets.
'Why is there a push to open up the private markets to 401(k)s now? It's not because workers want less liquid and harder-to-value assets in their 401(k)s. And it's not motivated by plan sponsors, who have long worried that exposing 401(k) plan participants to private market assets would violate their fiduciary duty to act in the best interest of the investors,' Schiffrin said in a statement. 'It's because private market firms are finding it harder now to raise money. Their traditional sources of funding — institutional investors such as pensions and endowments — have evaporated.'
Indeed, for plan sponsors, including private equity among their plan's investment options will require a lot more due diligence from them in terms of investigating the underlying investments in a given fund and examining the fee structure, Schlichter said. 'This is fraught with danger. A company that puts private equity in its 401(k) is undertaking a serious risk of breaching its fiduciary duty.'
Credit ratings agency Moody's this week put out an analysis, first reported by the Wall Street Journal, which cautioned that the accelerated push to give private capital firms access to the multitrillion-dollar retirement investment industry holds risk for everyone.
'Competition for retail investor capital within private markets will intensify as alternative asset managers roll out new partnerships and special funds to address this potentially vast, still largely untapped market,' the analysts wrote. 'But rapid growth within this still relatively opaque market also carries systemic implications.'
One example, they cited, is the potential for a liquidity crisis. 'Unlike institutional investors, retail investors expect ready access to their cash. To help, managers are launching products with periodic windows of liquidity. But in volatile markets, retail investors may run for the exits, which would exacerbate liquidity needs and the risk of potential mismatches between a product's available liquidity and what investors are expecting.'
The promise of investing in private equity is that the additional expense and risk assumed by investors can be rewarded with potentially strong returns over time.
While it's hard to easily and quickly track private equity performance on your own, there have been academic and industry studies on it, and the results have been mixed, said Jason Kephart, senior principal for multi-asset strategy ratings at Morningstar.
So, while you will likely pay more and have less transparency into what you're investing in, having a stake in private capital is no guarantee that you will enjoy meaningfully better returns in your portfolio.
As for the diversification argument, Kephart said, it's worth remembering that just as with public companies, private companies' performance will be affected by external forces such as economic downturns, interest rates, geopolitical concerns, tariffs and supply chain issues.
'Being private doesn't shield you from the world,' he noted.
And, Kephart added, 'It's not like the public markets are broken. Public stocks and bonds have paid off pretty well for those who've stayed invested.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Tulare County home listings asked for less money in May - see the current median price here
The median home in Tulare County listed for $419,975 in May, slightly down from the previous month's $421,778, an analysis of data from shows. Compared to May 2024, the median home list price slightly decreased from $424,975. The statistics in this article only pertain to houses listed for sale in Tulare County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Tulare County's median home was 1,774 square feet, listed at $244 per square foot. The price per square foot of homes for sale is up 1.6% from May 2024. Listings in Tulare County moved steadily, at a median 44 days listed compared to the May national median of 51 days on the market. In the previous month, homes had a median of 43 days on the market. Around 352 homes were newly listed on the market in May, a 15% increase from 306 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. In California, median home prices were $775,000, a slight increase from April. The median California home listed for sale had 1,775 square feet, with a price of $477 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Visalia Times-Delta: Tulare County home listings asked for less money in May - see the current median price here
Yahoo
10 minutes ago
- Yahoo
Wall Street Says Supermicro Stock Could Gain 60% in a Year
Super Micro Computer (SMCI) has weathered significant volatility in recent times, with its stock experiencing a rollercoaster ride. After reaching significant highs, the stock experienced steep declines due to a range of concerns, including allegations of accounting irregularities and a delay in filing its financial reports with the SEC. Nonetheless, SMCI stock has made an impressive recovery recently, climbing 50% year-to-date. 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Dear Tesla Stock Fans, Mark Your Calendars for June 30 Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Supermicro's stock came under heavy pressure following headlines that shook investor confidence. Allegations of accounting irregularities and a delay in filing annual reports sparked concerns about the possibility of delisting from the Nasdaq Exchange. The company eventually filed its financials, avoiding that outcome, but the damage to investor sentiment was already done. Adding to this were disappointing quarterly earnings. For its fiscal Q3 2025, Supermicro reported $4.6 billion in revenue, a 19% increase year-over-year but a 19% drop quarter-over-quarter. The results missed Wall Street's expectations, mainly due to customers holding back purchases amid uncertainty around new AI platform transitions, particularly Nvidia's (NVDA) move from Hopper to Blackwell GPU architecture. These delays contributed to the shortfall in expectations and added further pressure on the stock. These issues, however, now appear to be in the rearview mirror as those delays are beginning to turn into future growth opportunities. As customers resume spending, Supermicro appears poised to regain momentum. Furthermore, Supermicro recently announced a $20 billion partnership with Saudi Arabia-based DataVolt, which significantly boosted its stock. This deal strengthens the company's demand pipeline and will support future growth. Given these positive developments and continued investments in artificial intelligence (AI) infrastructure, SMCI stock is likely to trend higher. The highest price target for Supermicro stock is $70, courtesy of Loop Capital analyst Ananda Baruah. This target implies nearly 60% upside potential from here. Supermicro is well-positioned to benefit from secular tailwinds in the AI infrastructure market. The company specializes in building high-performance server and storage systems, many of which are now tailored specifically for AI workloads. This provides a significant runway for growth, as it strengthens the company's position to capitalize on AI demand. Thanks to the solid demand, over 70% of Supermicro's total revenue is now derived from AI GPU platforms, reflecting that the company could deliver significant growth as investments in AI continue to rise. Further, to meet the growing demand, Supermicro continues to expand its product portfolio. It has ramped up the production of its Data Center Building Block Solutions (DCBBS), which offer energy-efficient systems for next-generation computing. The company continues to roll out new products, including a range of air-cooled and liquid-cooled AI systems and racks. It has broadened its platform support to include AMD's newest AI accelerators. The expansion of SMCI's product portfolio is expected to help drive its market share higher. Supermicro is strengthening its leadership in the high-performance computing space with its technology to reduce environmental impact. The company's direct liquid cooling (DLC) technology helps lower energy costs, a critical factor as AI workloads become increasingly power-hungry. Furthermore, the rollout of its second-generation DLC-2 system will offer improved energy efficiency and thermal performance, which is expected to drive demand. Moreover, Supermicro's DCBBS reduces the time and complexity involved in building modern data centers. As the demand for scalable, plug-and-play infrastructure grows, DCBBS could become a significant growth driver for the company. The growing use of AI, which requires enhanced data center capabilities, will substantially increase demand for Supermicro's products. Supermicro's ability to design and deliver customized hardware solutions will help meet the specific needs of AI-driven workloads, strengthening its competitive positioning. Moreover, its focus on innovation, including energy-efficient green computing products and enhanced production of its DCBBS, positions it well to gain a higher market share. Analysts maintain a 'Moderate Buy' consensus rating on SMCI stock. However, given the strength of its product lineup and the booming demand in the AI and data center spaces, it wouldn't be surprising to see Supermicro's stock push toward the $70 mark in the near future. On the date of publication, Amit Singh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
